



# Role of less commonly agreed risk factors on disease recurrence in endometrial cancer: a propensity score-matched comparison

## Endometrial kanser rekürrensinde daha az kabul gören risk faktörlerinin rolü: eğilim puan eşleştirme karşılaştırması

© Hülya Ayık Aydın<sup>1</sup>, © Gülgün Erdoğan<sup>2</sup>, © Hatice Elif Pestereli<sup>2</sup>, © Tayup Şimşek<sup>1</sup>

<sup>1</sup>Akdeniz University Faculty of Medicine, Department of Obstetrics and Gynecology, Division of Gynecological Oncology, Antalya, Turkey

<sup>2</sup>Akdeniz University Faculty of Medicine, Department of Medical Pathology, Division of Gynecopathology, Antalya, Turkey

### Abstract

**Objective:** To compare the clinicopathologic features of patients with endometrial cancer (EC) with recurrent disease with a primary surgery, stage, grade, and tumor histotype-matched cohort of patients without recurrence.

**Materials and Methods:** Patients with EC who were surgically treated at a single tertiary care institution between 2005 and 2015 were enrolled in this study. The dataset included 381 consecutive patients with EC, of which 31 (8.1%) had disease recurrence. Data consisting of age at surgery, CA-125 concentration at diagnosis, number of lymph nodes harvested, growth pattern of the primary tumor, location of the primary tumor within the endometrium, tumor histotype, tumor grade, disease stage, adjuvant therapy, disease recurrence, time to recurrence, CA-125 concentration at recurrence, clinical and imaging findings at recurrence, and treatment modalities used for recurrent disease were extracted from the institutional database.

**Results:** After 1-to-1 propensity-score matching of patients with and without recurrence, the clinicopathologic features of 26 patients from each group were compared. Patients with recurrent disease were found to have a significantly higher CA-125 concentration at initial diagnosis ( $p<0.001$ ) and different tumor growth pattern ( $p=0.019$ ) than patients without disease recurrence. The papillary growth pattern of the primary tumor was significantly associated with disease recurrence as compared with polypoid and infiltrative patterns. Omental involvement, papillary tumor growth, and advanced age were associated with increased mortality.

**Conclusion:** Our results indicated that higher CA-125 concentrations at initial diagnosis and papillary growth pattern of primary tumors were found to be associated with disease recurrence.

**Keywords:** Endometrial cancer, recurrence, risk factor, CA-125

### Öz

**Amaç:** Rekürren hastalığı olan endometrial kanser (EC) hastalarının, primer cerrahi, evre, grade ve rekürrens saptanmayan tümör histotipi eşleştirilmiş kohortu ile klinikopatolojik özelliklerini karşılaştırmak.

**Gereç ve Yöntemler:** 2005 ve 2015 yılları arasında üçüncü basamak hastanede cerrahi olarak tedavi edilen hastalar bu çalışmaya dahil edildi. Veri seti, EC'si olan 381 ardışık hastayı içermekte olup, bunların 31'inde (%8,1) hastalık nüksü vardır. Cerrahi esnasındaki yaş, tanı sırasında CA-125 seviyesi, çıkarılan lenf nodu sayısı, primer tümörün büyüme paterni, endometriyumda primer tümörün yeri, tümör histotipi, tümör derecesi, hastalığın evresi, adjuvan tedavi, hastalık rekürrensi, rekürrens zamanı, rekürrenste CA-125 düzeyi, nükste klinik ve görüntüleme bulguları ve tekrarlayan hastalık için kullanılan tedavi yöntemleri kurumsal veri tabanından çıkarıldı.

**Bulgular:** Nüks olan ve olmayan hastaların 1'e 1'lik eğilim skoru eşleştirmelerinden sonra, her gruptan 26 hastanın klinikopatolojik özellikleri karşılaştırıldı. Rekürren hastalığı olan hastalarda, olmayanlarla karşılaştırıldığında tümör büyüme paterninde ( $p=0,019$ ) ve başlangıçtaki CA-125 seviyesinde anlamlı bir artış saptandı. Primer tümörün papiller büyüme paterni, polipoid ve infiltratif modellere kıyasla hastalık nüksü ile anlamlı olarak ilişkiliydi. Omental tutulum, papiller tümör büyümesi ve ileri yaş artmış mortalite ile ilişkiliydi.

**Sonuç:** Bulgularımız, ilk tanıdaki yüksek CA-125 seviyesinin ve primer tümörün papiller büyüme paterninin hastalık nüksüyle ilişkili olduğunu göstermiştir

**Anahtar Kelimeler:** Endometrial kanser, rekürrens, risk faktör, CA-125

**PRECIS:** Role of less commonly agreed risk factors on disease recurrence in endometrial cancer: A propensity score- matched comparison.

Address for Correspondence/Yazışma Adresi: Hülya Ayık Aydın,

Akdeniz University Faculty of Medicine, Department of Obstetrics and Gynecology, Division of Gynecological Oncology, Antalya, Turkey

E-mail: hulya\_ayik@hotmail.com ORCID ID: orcid.org/0000-0002-3028-7247

Received/Geliş Tarihi: 13.09.2018 Accepted/Kabul Tarihi: 07.02.2019

©Copyright 2019 by Turkish Society of Obstetrics and Gynecology

Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.

## Introduction

Endometrial cancer (EC) is the most common cancer of the female genitourinary system in the United States of America and the 4<sup>th</sup> most common tumor in Western countries, with more than 280.000 patients appearing yearly, globally<sup>(1)</sup>. Nevertheless, data reveal that the mortality rate is rising more quickly than the incidence, possibly because of an improved rate of advanced-stage tumors, high-risk histopathologies, and cases being identified in the elderly<sup>(2)</sup>. Consequently, 13-17% of patients will develop disease recurrence, usually within three years of initial treatment<sup>(3,4)</sup>.

Although most with EC are diagnosed with early-stage disease and have a favorable prognosis, approximately 15% of these cases relapse<sup>(5)</sup>. Treatment for recurrence includes local treatment (radiotherapy or surgery), systemic chemotherapy or relevant combinations. It differs according to the involved site, recurrent disease extent, and types of previous therapy. The 3-year survival rate in patients with EC recurrence is reported to be between 8% and 73%<sup>(6)</sup>. This broad range indicates that patients with EC recurrence represent a heterogeneous group with different prognostic factors for survival. Thus, there is a need to better discriminate these patients depending on prognosis after relapse. Numerous features have been examined to evaluate their effect on recurrence; patient's age at diagnosis, the stage, histologic type, cell type, cervical involvement, depth of myometrial invasion, and lymph node metastasis at the time of treatment were identified as the most significant prognostic factors in patients with EC<sup>(7,8)</sup>. Nevertheless, these factors are not satisfactory to precisely predict the prognosis of these patients. There is a common consensus that disease stage, tumor histotype, and tumor grade are significantly associated with risk of recurrence in EC. To examine the roles of less commonly agreed risk factors on disease recurrence, we compared the clinicopathologic features of patients with recurrent disease with a primary surgery, stage, grade, and tumor histotype-matched cohort of patients without recurrence.

## Materials and Methods

### Study design

The study was approved by the Akdeniz University Faculty of Medicine Ethics Committee (no: 15/03.01.2018). All patients gave written informed consent, which allowed the participating institution to use their clinical data. Patients with EC who were surgically treated at a single tertiary care institution between 2005 and 2015 were enrolled in this study.

In the present study, recurrence was defined as any documented reappearance of cancer, either locally or systemically, after a disease-free interval of  $\geq 3$  months. Local-regional recurrence was defined as relapse at the vaginal vault or in the regional lymph nodes including pelvic and paraaortic nodes.

Abdominal/peritoneal recurrence was defined as relapse at the peritoneum, omentum or serosal surfaces of the abdominal viscera, or occurrence of malignant ascites. Distant metastasis was defined as any relapse at extraabdominal organs and lymph nodes, or in the parenchyma of the intraperitoneal organs.

Routine post-remission surveillance at our institution was to follow up patients every three months for two years, every six months for the next three years, and then annually. At follow-up visits, a physical examination, ultrasonography, complete blood count, and blood chemistry including serum CA-125 level were performed. Thoracic and abdominal computed tomography scans were used six-monthly for two years and then annually. In the event of equivocal clinical or radiologic findings, positron emission tomography combined with computed tomography (PET-CT) was performed. Image-guided biopsy was used whenever possible, and there was a high suspicion of disease recurrence before the treatment of recurrence was started.

### Outcome parameters

Data consisting of age at surgery, CA-125 concentration at diagnosis, time from diagnosis to primary treatment, type of surgical procedure performed, number of lymph nodes harvested, growth pattern of the primary tumor, location of the primary tumor within the endometrium, tumor histotype, tumor grade, disease stage, adjuvant therapy, disease recurrence, time to recurrence, CA-125 concentration at recurrence, clinical and imaging findings at recurrence, largest recurrent tumor size, extent of recurrent disease, number of recurrent lesions, and treatment modalities used for recurrent disease were extracted from the institutional database.

### Statistical Analysis

The dataset included 381 consecutive patients with EC, of which 31 (8.1%) had disease recurrence. A 1-to-1 propensity score-matched analysis was conducted to provide matched cohorts of patients with and without recurrence, and thus, to reduce the impact of covariate bias. Multivariate logistic regression models were used to develop separate propensity scores. Disease stage, tumor grade, tumor histotype, and primary surgery [total hysterectomy/bilateral salpingo-oophorectomy (TH/BSO) alone vs. TH/BSO plus lymphadenectomy] were selected as potential confounding covariates because they are known to be independent factors for risk of recurrence and to be the main determinants of prognosis in patients with EC. For tight matching, nearest-neighbor matching was performed with a caliper width (the match tolerance) equal to 0.01, which resulted in successful matching of 26 patients from each group. A simple logistic regression analysis was then performed using the matched groups to assess independent associations of clinicopathologic factors and disease recurrence. The differences between

two groups were tested using the Mann-Whitney U test for nonparametric data. The chi-square or Fisher's exact tests were used for the comparison of categorical variables.

Statistical analyses were performed using NCSS (Number Cruncher Statistical System) 2007 statistical software (NCSS LLC, Kaysville, Utah, USA). A two-tailed  $p < 0.05$  was considered statistically significant.

The cut-off point for CA-125 was determined using receiver operating characteristics (ROC) analysis based on the survival data. Survival analysis was performed to investigate the survival probabilities of variables. The mean durations of survival, 95% confidence intervals, as well as hazard ratios are presented.

## Results

Table 1 shows the baseline characteristics of 381 patients with EC. Eighty percent of patients had endometrioid tumor histotype. According to the International Federation of Obstetricians and Gynecologists (FIGO) grading system, 52% of patients had grade 1 tumor, 30.2% had grade 2, and 17.6% had grade 3. The patients treated with TH/BSO plus lymphadenectomy accounted for 90.6%. The median number of lymph nodes harvested was 30. The FIGO<sub>2009</sub> stages of the patients were as follows: stage IA, 179 patients (47.0%); stage IB, 110 patients (28.9%); stage II, 25 patients (6.6%); stage IIIA, 8 patients (2.1%); stage IIIB, 1 patient (0.3%); stage IIIC, 46 patients (12.1%); and stage IVB, 12 patients (3.1%). Adjuvant therapy was given to 55.4% of the patients. Thirty-one patients (8.1%) developed disease recurrence during a median follow-up time of 68 months.

The characteristics of the 31 patients with recurrent disease are presented in Table 2. The median time to recurrence was 15 (range, 3 to 46) months. Only five patients (16.1%) first presented with abnormal clinical signs and/or symptoms, but none had positive physical findings alone. At the time of the diagnosis of recurrence, all patients had positive imaging findings and 26 (83.9%) had elevated CA-125 concentrations. On the other hand, only 2 (6.5%) patients were incidentally diagnosed through routine imaging studies alone. The majority (74.2%) of patients developed multiple or disseminated metastases. Recurrent disease was limited to the vaginal vault and/or regional lymph nodes in only 19.4% of patients. The liver was the most common site of distant metastasis, found in 22.6% of patients.

After 1-to-1 propensity-score matching of patients with and without recurrence based on stage, grade, histotype, and primary surgery, the clinicopathologic features of 26 patients from each group were compared (Table 3). Study groups were comparable for age at surgery, time from diagnosis to primary treatment, number of lymph nodes harvested, location of the primary tumor within the endometrium, lymphovascular space involvement, cervical invasion, positive peritoneal cytology, and adjuvant therapies received.

**Table 1.** Initial surgical and pathologic characteristics of 381 patients with endometrial cancer

Variables	Values
Age, median (range), years	58 (24-88)
CA-125 concentrations at diagnosis, median (range), U/mL	30 (3.2-1172)
Time from diagnosis to primary treatment, median (range), days	12 (1-45)
Primary surgery, n (%)	
TH/BSO alone	36 (9.4)
TH/BSO plus lymphadenectomy (pelvic ± paraaortic)	345 (90.6)
No. of lymph nodes harvested, median (range)	30 (0-107)
Growth pattern of the primary tumor, n (%)	
Polypoid	150 (39.4)
Infiltrative	123 (32.3)
Papillary	108 (28.3)
Tumor location within the endometrium, n (%)	
Fundus	70 (18.4)
Corpus	159 (41.7)
Isthmus	19 (5.0)
Involving the whole cavity	133 (34.9)
Histotype, n (%)	
Endometrioid	306 (80.3)
Non-endometrioid	75 (19.7)
FIGO grade, n (%)	
Grade 1	199 (52.2)
Grade 2	115 (30.2)
Grade 3	67 (17.6)
FIGO stage, n (%)	
IA	179 (47.0)
IB	110 (28.9)
II	25 (6.6)
IIIA	8 (2.1)
IIIB	1 (0.3)
IIIC	46 (12.1)
IVB	12 (3.1)
Adjuvant therapy, n (%)	211 (55.4)
Radiotherapy alone (EBRT and/or brachytherapy)	137 (36.0)
Chemotherapy ± radiotherapy	74 (19.4)
Follow-up time, median, (95% CI), months	68 (1-144)
Disease recurrence, n (%)	31 (8.1)

TH/BSO: Total hysterectomy bilateral salpingo-oophorectomy, FIGO: International Federation of Gynecology and Obstetrics, EBRT: External beam radiotherapy, CI: Confidential interval

**Table 2.** Characteristics of 31 patients with recurrent disease

Variables	Values
Time to recurrence, median (range), months	15 (3-46)
CA-125 concentration at recurrence, median (range), U/mL	66 (9.6-962)
Diagnosis of recurrence, n (%)	
Positive clinical findings	5 (16.1)
Elevated CA-125 concentrations	26 (83.9)
Positive imaging findings	31 (100)
With normal CA-125 concentration and negative clinical findings	2 (6.5)
Largest recurrent tumor size, median (range), cm	3.5 (0.7-12)
No. of recurrent lesions, n (%)	
Isolated metastasis	8 (25.8)
Multiple/disseminated metastases	23 (74.2)
Disease extent at recurrence, n (%)	
Local-regional disease	6 (19.4)
Confined to the vaginal cuff	4 (12.9)
Abdominal/peritoneal disease	14 (45.2)
Distant metastasis	11 (35.5)
Liver	7 (22.6)
Lung	3 (9.7)
Brain	1 (3.2)
Musculoskeletal soft tissue	1 (3.2)
Extraabdominal lymph nodes	2 (6.5)
Treatment modalities used for recurrent disease, n (%)	
Surgical resection	2 (6.5)
Radiotherapy	2 (6.5)
Chemotherapy	29 (93.5)


However, patients with recurrent disease were found to have a significantly greater tumor size ( $p=0.026$ ), higher CA-125 concentration at initial diagnosis ( $p<0.001$ ), and different tumor growth pattern ( $p=0.019$ ) than patients without disease recurrence. The papillary growth pattern of the primary tumor was significantly associated with disease recurrence as compared with polypoid and infiltrative patterns.

Elevated CA-125 concentration and papillary growth pattern did not exhibit a significant difference between type I and type II cancers ( $p=0.267$  and  $p=0.429$ , respectively). Table 4 demonstrates a comparative overview for histological grade, histological type, and staging data for tumors with and without recurrence. As would be expected, advanced grade and tumor stage were significantly associated with increased recurrence.


As shown in Table 5, analysis of the impacts of parameters on survival indicated that patients with tumoral involvement of omentum were at 5.712-times greater risk for mortality. Papillary tumors were 4.67 times more lethal compared with non-papillary neoplasms. Mortality was 1.041 times more likely for every advanced year.

ROC analysis was used to determine the cut-off point for CA-125 concentrations. Taking mortality into account as the gold standard, the cut-off point was determined as 44.1 with a sensitivity and specificity of 72.6% and 60%, respectively. The ROC curve is demonstrated in Figure 1.

Kaplan-Meier analyses for omental involvement and papillary tumor patterns are indicated in Figures 2 and 3, respectively.



**Figure 1.** ROC curve for CA-125 levels



**Figure 2.** Kaplan-Meier analysis for omental involvement


**Discussion**

In the present study, we aimed to compare the clinicopathologic features of patients with recurrent disease with a primary

**Table 3.** Comparison of clinicopathologic features of matched cohorts with and without recurrence

	Recurrent disease		p
	Yes (n=26)	No (n=26)	
Age at surgery, median (range), years	63 (48-74)	62 (44-74)	0.219
Tumor size (cm), mean ± SD	5.2±4.2	3.3±1.9	0.026
CA-125 level at initial diagnosis, median (range), U/mL	71.5 (30-1172)	29 (8.5-57)	<0.001
Time from diagnosis to primary treatment, median (range), days	12.5 (3-27)	10 (3-25)	0.212
Number of lymph nodes harvested, median (range)	36 (10-79)	29 (11-52)	0.084
Growth pattern of the primary tumor, n (%)			
Polypoid	10 (38.5)	15 (57.7)	0.019
Infiltrative	7 (26.9)	10 (38.5)	
Papillary	9 (34.6)	1 (3.8)	
Primary tumor location, n (%)			
Fundus	5 (19.2)	4 (15.4)	0.856
Corpus	7 (26.9)	9 (34.6)	
Isthmus	5 (19.2)	3 (11.5)	
Involving the whole cavity	9 (34.6)	10 (38.5)	
Lymphovascular space involvement, n (%)	8 (30.8)	5 (19.2)	0.337
Cervical invasion	9 (34.6)	7 (26.9)	0.548
Positive peritoneal cytology, n (%)	2 (7.7)	3 (11.5)	0.999
Adjuvant therapy, n (%)	23 (88.5)	25 (96.2)	0.610

Bold values indicate statistical significance at  $p < 0.05$

**Figure 3.** Kaplan-Meier analysis for papillary tumor growth pattern

surgery, stage, grade, and tumor histotype-matched cohort of patients without recurrence. We found that higher CA-125 concentrations at initial diagnosis and a papillary growth pattern of the primary tumor were associated with disease recurrence.

In the present study, the ratio of recurrence after the initial treatment of EC was 8.1%. This rate is slightly lower than

previously described in other reports<sup>(4-6)</sup>. The low recurrence rates obtained in our study may be due to the patient characteristics in the study group or may be a result of the extensive surgical interventions and/or adjuvant radiotherapy, and chemotherapy being applied. The relation of EC recurrences and the interval passed from initial treatment for EC indicates that time to recurrence was detected with a median of 15 months. These data are in accordance with ratios described by other reports<sup>(6-8)</sup>.

In the present study, our data confirmed a tendency described by the mainstream of reports that distant recurrences are more frequent than local recurrences after the initial treatment of EC. This is possibly due to pelvic adjuvant radiotherapy following surgical procedures. The present study demonstrated findings that are very comparable to the other reports<sup>(9,10)</sup>. Sohaib et al.<sup>(9)</sup> reported 34.4% local recurrences, 46.9% distant recurrences, and 18.8% in both sites, and Fung-Fee-Fung et al.<sup>(10)</sup> reported 61% of distant metastases including multifocal relapses and 39% of local recurrences.

Although serum concentrations of CA-125 have been used as a worthy tumor marker for EC diagnosis and recurrence detection after the initial treatment, their role as a useful tumor marker in EC is the subject of debate<sup>(11)</sup>. Several reports

**Table 4.** Comparison of histologic grade and type, and staging in patients with and without tumor recurrence

Variable	Subgroup	Recurrence		P
		No (n, %)	Yes (n, %)	
Histological grade	1	202 (57.7)	2 (6.4)	<0.001*
	2	78 (22.3)	7 (22.6)	
	3	19 (5.4)	22 (71)	
	Data unavailable	51 (14.6)	0	
Stage	1A	167 (47.7)	7 (22.6)	<0.001*
	1B	88 (25.1)	7 (22.6)	
	2	23 (6.6)	2 (6.5)	
	3A	7 (2.0)	1 (3.2)	
	3B	1 (0.3)	0 (0)	
	3C	7 (2.0)	1 (3.2)	
	3C1	13 (3.7)	1 (3.2)	
	3C2	19 (5.4)	5 (16.1)	
	4B	5 (1.4)	7 (22.6)	
Histological type	Endometrioid	292 (83.4)	14 (45.2)	N/A
	Mucinous	6 (1.7)	0 (0)	
	Serous	6 (1.7)	5 (16.1)	
	Clear cell	9 (2.6)	3 (9.7)	
	Mixed	19 (5.4)	3 (9.7)	
	Undifferentiated	3 (0.9)	0 (0)	
	MMMT	14 (4.0)	6 (19.4)	
	Other	1 (0.3)	0 (0)	

\*: Statistically significant, MMT: Malignant mixed Müllerian tumor, N/A: Analysis not applicable due to small number of cases in some subgroups, bold values imply statistical significance

have revealed that serum levels of CA-125 are critical for preoperative diagnosis and prediction of the recurrence, and that their elevation was associated with advanced-stage EC<sup>(12)</sup>. Yildiz et al.<sup>(13)</sup> showed that the CA-125 serum concentration increase was related with the upsurge in extra-uterine disease incidence. Similarly, Chen et al.<sup>(14)</sup> revealed that elevated CA-125 concentrations were intensely correlated with lymph node metastasis, advanced surgical stage, and poor prognosis<sup>(13,14)</sup>. Elevated serum concentrations of CA-125 at initial diagnosis are linked with extrauterine tumor extension and lymph node metastases<sup>(15,16)</sup>. In the present study, patients with recurrent disease were observed to have a significantly higher CA-125 concentration at initial diagnosis.

Abnormal preoperative cytology was demonstrated to be associated with a number of poor prognostic features such as tumor grade, degree of myometrial invasion, and lymph node spread<sup>(17-19)</sup>. Abnormal cytology is correlated with advanced-stage for both endometrioid and papillary serous or clear cell histologic subtypes<sup>(18,19)</sup>. The aggressive performance of the papillary subtype was firstly defined by Hendrickson et

al.<sup>(20)</sup> as a subtype of EC with precise pathologic and clinical features related with a high frequency of tumor recurrence. Papillary subtype represents 3-10% of all ECs but accounts for nearly 40% of EC deaths<sup>(20,21)</sup>. In a recent study of patients with EC, cervical cytology was revealed to be an individual predictor of lymph node spread<sup>(18)</sup>. Regardless of the strong connection between abnormal cytology and recurrence, the direct association between abnormal cytology and recurrence risk has not been comprehensively assessed. Fukuda et al.<sup>(19)</sup> stated that abnormal cytology was associated with disease-free survival in univariate analysis but was not an independent predictor of survival on multivariate analysis. In the present study, papillary growth pattern of the primary tumor was significantly associated with disease recurrence as compared with polypoid and infiltrative patterns. Our results yielded that omentum involvement, papillary-type tumor growth, and advanced age were linked with mortality risk.

There is an increasing awareness in observational reports of the need to assess the effects of treatment on results. In observational and nonrandomized studies, treatment choice

**Table 5.** The effect of various parameters on survival

Variable	Mean	Survival time (week)			P Estimate	Hazard ratio		
		95% CI				95% CI		
		Lower	Upper			Lower	Upper	
Polyp	Negative*	359.54	273.53	445.55	0.268	1.411	0.764	2.605
	Positive	205.95	139.73	272.16				
Myoma	Negative	287.09	206.25	367.93	0.073	1.823	0.936	3.55
	Positive*	359.81	254.99	464.62				
Adenomyosis	Negative*	346.96	257.5	436.41	0.520	1.205	0.682	2.129
	Positive	229.18	158.61	299.77				
LVSI	Negative*	352.03	270.03	434.03	0.523	1.443	0.739	2.816
	Positive	211.79	133.45	310.12				
Differentiation	Poor*	340.363	243.32	437.40	0.305	1.349	0.759	2.399
	Moderate	208.57	147.12	270.02				
Omentum Involvement	Negative*	507.16	415.34	598.96	<0.001	5.712	2.251	14.493
	Positive	231.66	165.52	297.78				
Pathologic subtype	Papillary	289.89	217.95	361.85	0.019	4.668	1.128	19.317
	Others*	495.42	345.73	645.10				
CA-125	441*	352.59	256.89	448.29	0.336	1.614	0.897	2.904
	>441	273.84	195.03	352.64				
Age					<0.001	1.041	1.019	1.064

(\*: Reference category) CI: Confidence intervals, LVSI: Lymphovascular space invasion

is frequently affected by patient individualities. Consequently, researchers have to account for for systematic alterations in baseline features amongst compared groups when assessing the result of treatment on outcomes. Lately, when using observational data, there has been growing concern regarding techniques established on the propensity score to decrease or eradicate the outcomes of confounding<sup>(22)</sup>.

Some limitations of the present study should be mentioned. First, the retrospective nature of the study causes bias. Secondly, this was a single-institution study, and caution must be taken before generalizing the conclusions to further settings. Another limitation is the long study period because study group comprised patients who experienced distinct surgical treatment (i.e. systematic pelvic lymphadenectomy was only recommended for high-risk ECs from 2010)<sup>(23)</sup>. Thirdly, physical activity, diet, and presence of chronic diseases such as hypertension or diabetes were not taken into account, though numerous investigators have formerly shown that these features might normalize endometrial hormone-receptor expressions and definitely effect survival<sup>(24,25)</sup>.

## Conclusion

Higher CA-125 concentrations at initial diagnosis and a papillary growth pattern of the primary tumor were found to

be associated with disease recurrence. Omental involvement, papillary tumor growth, and advanced age were found to increase mortality rates. Further randomized, prospective, controlled trials on larger series are necessary for making more precise interpretations.

## Acknowledgments

The authors received no financial support for the research, authorship, and/or publication of this article.

## Ethics

**Ethics Committee Approval:** The study was approved by the Akdeniz University Faculty of Medicine Ethics Committee (no: 15/03.01.2018)

**Informed Consent:** All patients gave written informed consent, which allowed the participating institution to use their clinical data.

**Peer-review:** External and internal peer-reviewed.

## Authorship Contributions

Surgical and Medical Practices: T.Ş., H.A.A., Concept: G.E., Design: H.A.A., Data Collection or Processing: H.A.A., Analysis or Interpretation: H.E.P., Literature Search: H.A.A., Writing: H.A.A.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

## References

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]. Lyon: International Agency for Research on Cancer; 2013.
2. Ueda SM, Kapp DS, Cheung MK, et al. Trends in Demographic and Clinical Characteristics in Women Diagnosed with Corpus Cancer and Their Potential Impact on the Increasing Number of Deaths. *Am J Obstet Gynecol* 2008;198:218.e211-6.
3. Lukka H, Chambers A, Fyles A, Thephamongkhon K, Fung-Kee-Fung M, Elit L et al. Adjuvant radiotherapy in women with stage I endometrial cancer: a systematic review. *Gynecologic Oncol* 2006;102:361-8.
4. Smith CJ, Heeren M, Nicklin JL, et al. Efficacy of Routine Follow-up in Patients with Recurrent Uterine Cancer. *Gynecol Oncol* 2007;107:124-9.
5. Frandsen JE, Sause WT, Dodson MK, et al. Survival Analysis of Endometrial Cancer Patients with Cervical Stromal Involvement. *J Gynecol Oncol* 2014;25:105-10.
6. Creutzberg CL, van Putten WL, Koper PC, et al. Survival After Relapse in Patients with Endometrial Cancer: Results From a Randomized Trial. *Gynecol Oncol* 2003;89:201-9.
7. Yoshida T, Takei Y, Machida S, et al. Prognosis of Endometrial Cancer Patients with and without Symptoms at Recurrence. *J Obstet Gynaecol Res* 2016;42:1814-21.
8. Ouldamer L, Bendifallah S, Body G, et al. Predicting Poor Prognosis Recurrence in Women with Endometrial Cancer: A Nomogram Developed by the FRANCOGYN Study Group. *Br J Cancer* 2016;115:1296-1303.
9. Sohaib SA, Houghton SL, Reznik RH et al. Recurrent Endometrial Cancer: Patterns of Recurrent Disease and Assessment of Prognosis. *Clin Radiol* 2007;62:28-34.
10. Fung-Kee-Fung M, Dodge J, Elit L, et al. Follow-up After Primary Therapy for Endometrial Cancer: A Systematic Review. *Gynecol Oncol* 2006;101:520-9.
11. Kotowicz B, Fuksiewicz M, Jonska-Gmyrek J, et al. Preoperative Serum Levels Of YKL 40 and CA125 as A Prognostic Indicators in Patients With Endometrial Cancer. *Eur J Obstet Gynecol Reprod Biol* 2017;215:141-7.
12. Rose PG, Sommers RM, Reale FR, et al. Serial Serum CA 125 Measurements for Evaluation of Recurrence in Patients with Endometrial Carcinoma. *Obstet Gynecol* 1994;84:12-6.
13. Yildiz A, Yetimlar H, Kasap B, et al. Preoperative Serum CA 125 Level in the Prediction of the Stage of Disease in Endometrial Carcinoma. *Eur J Obstet Gynecol Reprod Biol* 2012;164:191-5.
14. Chen YL, Huang CY, Chien TY, et al. Value Of Pre-Operative Serum CA125 Level for Prediction of Prognosis in Patients with Endometrial Cancer. *Aust N Z J Obstet Gynaecol* 2011;51:397-402.
15. Yamazawa K, Hirashiki K, Usui H, et al. Discordance Between Serum Level and Tissue Immunohistochemical Staining of CA125 in Endometrioid Adenocarcinoma of the Uterine Corpus. *Int J Gynecol Pathol* 2005;24:254-9.
16. Hsieh CH, ChangChien CC, Lin H, et al. Can a Preoperative CA 125 Level Be A Criterion for Full Pelvic Lymphadenectomy in Surgical Staging of Endometrial Cancer? *Gynecol Oncol* 2002;86:28-33.
17. DuBeshter B. Endometrial Cancer: Predictive Value of Cervical Cytology. *Gynecol Oncol* 1999;72:271-2.
18. DuBeshter B, Deuel C, Gillis S, et al. Endometrial Cancer: The Potential Role of Cervical Cytology in Current Surgical Staging. *Obstet Gynecol* 2003;101:445-50.
19. Fukuda K, Mori M, Uchiyama M, et al. Preoperative Cervical Cytology in Endometrial Carcinoma and its Clinicopathologic Relevance. *Gynecol Oncol* 1999;72:273-7.
20. Hendrickson M, Ross J, Eifel P, et al. Uterine Papillary Serous Carcinoma: A Highly Malignant Form of Endometrial Adenocarcinoma. *Am J Surg Pathol* 1982;6:93-108.
21. O'Hanlan KA, Levine PA, Harbatkin D, et al. Virulence of Papillary Endometrial Carcinoma. *Gynecol Oncol* 1990;37:112-9.
22. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. *Multivariate Behav Res* 2011;46:399-424.
23. Cancer de l'endomètre, Collection Recommandations & référentiels, Boulogne-Billancourt: INCa; Nov 2010.
24. Pekmezi DW, Demark-Wahnefried W. Updated Evidence in Support of Diet and Exercise Interventions in Cancer Survivors. *Acta Oncol* 2011;50:167-78.
25. Karaman E, Karaman Y, Numanoglu C, Ark HC. Evaluation of hemoglobin A1c Levels in Endometrial Cancer Patients: a Retrospective Study in Turkey. *Asian Pac J Cancer Prev* 2015;16:1817-20.